Edwards Lifesciences Corp. (NYSE:EW) received a $140.00 target price from equities researchers at Canaccord Genuity in a note issued to investors on Monday. The firm currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity’s price objective points to a potential upside of 66.87% from the company’s current price.

A number of other research firms have also commented on EW. Leerink Swann restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Morgan Stanley restated a “buy” rating and set a $140.00 price objective on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Credit Suisse Group AG set a $116.00 price objective on Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research note on Thursday, August 18th. Evercore ISI restated a “hold” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Sunday, September 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $117.28.

Analyst Recommendations for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) opened at 83.90 on Monday. Edwards Lifesciences Corp. has a 52 week low of $72.20 and a 52 week high of $121.75. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of 33.16 and a beta of 0.71. The stock’s 50 day moving average price is $99.49 and its 200 day moving average price is $106.55.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.68. The business earned $739.40 million during the quarter, compared to analysts’ expectations of $749.14 million. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the firm posted $0.54 EPS. On average, equities research analysts predict that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/edwards-lifesciences-corp-ew-given-a-140-00-price-target-by-canaccord-genuity-analysts-2.html.

In other Edwards Lifesciences Corp. news, VP Larry L. Wood sold 13,257 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $119.27, for a total transaction of $1,581,162.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Huimin Wang sold 13,650 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $120.04, for a total value of $1,638,546.00. The disclosure for this sale can be found here. Company insiders own 2.37% of the company’s stock.

Hedge funds have recently modified their holdings of the company. CenturyLink Investment Management Co bought a new stake in shares of Edwards Lifesciences Corp. during the second quarter worth approximately $207,000. British Columbia Investment Management Corp raised its stake in shares of Edwards Lifesciences Corp. by 11.7% in the second quarter. British Columbia Investment Management Corp now owns 145,782 shares of the medical research company’s stock worth $14,539,000 after buying an additional 15,291 shares in the last quarter. Exxonmobil Investment Management Inc. TX raised its stake in shares of Edwards Lifesciences Corp. by 4.9% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 54,815 shares of the medical research company’s stock worth $5,467,000 after buying an additional 2,566 shares in the last quarter. Capstone Asset Management Co. raised its stake in shares of Edwards Lifesciences Corp. by 10.2% in the second quarter. Capstone Asset Management Co. now owns 26,363 shares of the medical research company’s stock worth $2,629,000 after buying an additional 2,432 shares in the last quarter. Finally, Pure Financial Advisors Inc. raised its stake in shares of Edwards Lifesciences Corp. by 17.8% in the second quarter. Pure Financial Advisors Inc. now owns 4,118 shares of the medical research company’s stock worth $411,000 after buying an additional 623 shares in the last quarter. 83.08% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.